Clinical trials: Persistent Negative Symptoms
Schizophrenia
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
This multi-center, randomized, double blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192906
- Testing
- bitopertin [RO4917838]
- Where
- 113 sites in United States, Brazil and 12 more
- Volunteers
- 624 people
- Sponsor
- Hoffmann-La Roche
Recurrent or Persistent Endometrial Carcinoma
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent…
- Trial name
- NCT02064725
- Testing
- Sodium cridanimod
- Where
- 21 sites in United States, Belarus and 3 more
- Volunteers
- 8 people
- Sponsor
- Kevelt AS
Post-Treatment Lyme Disease Syndrome
Ceftriaxone for Post-Treatment Lyme Disease
Lyme disease is a public health crisis in the US. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop Post-Treatment Lyme disease Syndrome (PTLDS).
- Trial name
- NCT06785402
- Testing
- Ceftriaxone treatment
- Where
- United States
- Sponsor
- Hackensack Meridian Health
Schizophrenia
SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia
The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.
- Trial name
- NCT01760889
- Testing
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg)
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Shire
Schizophrenia
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
- Trial name
- NCT03793712
- Testing
- Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day)
- Where
- 53 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 168 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia; Negative Type
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Theta Burst Stimulation in Schizophrenia Patients With Persistent Negative Symptoms
Schizophrenia patients commonly present with persistent negative symptoms which remain the main reason for dysfunction after recovery from an acute episode of psychotic symptoms.
- Trial name
- NOBLE-TMS (NCT06351514)
- Testing
- Accelerated iTBS
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Institute of Mental Health, Singapore
Schizophrenia
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
- Trial name
- NCT00977522
- Testing
- PF-03463275
- Where
- 37 sites in United States
- Volunteers
- 207 people
- Sponsor
- Pfizer
Mental Disorders, Schizophrenia
STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia
This project aims to provide the proof of concept for transcranial direct-current stimulation (tDCS) in the treatment of resistant/persistent Schizophrenia symptoms.
- Trial name
- STIM'ZO (NCT02744989)
- Testing
- Neuroconn or Neuroelectric tDCS stimulator
- Where
- 10 sites in France, Monaco
- Volunteers
- 141 people
- Sponsor
- Hospices Civils de Lyon
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Post-Treatment Lyme Disease
Meditation and Kundalini Yoga for Persistent Lyme-related Symptoms - an Online Study
This randomized, controlled study examines whether a daily practice over 8 weeks of Kundalini Yoga or Meditation can help to reduce pain and/or fatigue among patients with symptoms that persist despite prior antibiotic treatment.
- Trial name
- NCT04349605
- Testing
- Meditation, Kundalini Yoga
- Sponsor
- Research Foundation for Mental Hygiene, Inc.
Phantom Limb Pain After Amputation, Chronic Pain Due to Injury
Negative Pressure Wound Therapy as a Predictor of Persistent Pain After War-Related Trauma
War-related trauma frequently causes complex soft tissue injuries that require repeated surgical treatment and advanced wound management techniques such as Negative Pressure Wound Therapy (NPWT).
- Conditions
- Phantom Limb Pain After Amputation, Chronic Pain Due to Injury, Postoperative Pain, Trauma (Including Fractures)
- Trial name
- NPWT-Pain Stud (NCT07475897)
- Where
- Ukraine
- Volunteers
- 150 people
- Sponsor
- Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans)
Schizophrenia
Promoting Activity and Cognitive Enrichment in Schizophrenia (PACES)
This project will conduct a confirmatory efficacy trial of two novel psychosocial interventions, Cognitive Enhancement Therapy and Enriched Supportive Therapy, for the treatment of persistent negative symptoms in schizophrenia.
- Trial name
- NCT04143126
- Testing
- Cognitive Enhancement Therapy, Enriched Supportive Therapy
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Pittsburgh
Schizophrenia
A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)
This multi-center, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in participants with persistent, predominant negative symptoms of schizophrenia.
- Trial name
- NCT01192867
- Testing
- RO4917838, Antipshychotics (Standard of Care)
- Where
- 122 sites in United States, Argentina and 12 more
- Volunteers
- 629 people
- Sponsor
- Hoffmann-La Roche